



Sequella, Inc.
9610 Medical Center Drive
Rockville, MD 20850
Tele: 301-762-7776
www.sequella.com

NEWS RELEASE
FOR IMMEDIATE RELEASE

Sequella Presentation at the 36th IUATLD World Conference on Lung Health

ROCKVILLE, Md, October 11, 2005-- Sequella, Inc., a privately held biotechnology company developing infectious disease products, will be presenting an update on their drug discovery program for the indication tuberculosis at the 36th IUATLD World Conference on Lung Health in Paris, France (www.worldlunghealth.org/Conf2005/index.php) The theme of the 2005 conference, which will take place from October 18, 2005 to October 22, 2005, is "Scaling up and sustaining effective tuberculosis, HIV and asthma prevention and control".

Dr. Marina Protopopova, Sequella's VP for Drug Discovery is scheduled to present, "**Novel Drug Candidates Targeting the Cell Wall of Mycobacterium Tuberculosis**" in the Recent Advances in TB Drug Development section on Thursday, October 20, 2005.

The update will include the Sequella portfolio of proprietary cell wall inhibiting agents such as the drug candidate SQ109, SQ609, and translocase inhibitor series. This symposium is hosted by the TB Alliance with support from the Stop TB Partnership.

About Sequella, Inc.

Sequella, Inc. is a clinical stage biotechnology company, developing and commercializing novel infectious disease diagnostic and therapeutic products. The company's lead product candidate, the Transdermal Patch for diagnosis of active TB disease, is being tested in an international phase III clinical trial, with over 50% of patients already enrolled in six clinical centers. Sequella conducts discovery and pre-clinical research at its Rockville headquarters, which houses chemistry and microbiology laboratories, and a BSL-3 facility. For more information, please visit www.sequella.com.

MEDIA CONTACT:

Henrik Wranaker
Corporate Development
Ph: 301-762-7776
Fax: 301-762-7778
henrikwranaker@sequella.com